{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:24:35Z","timestamp":1790501075558,"version":"4.1.0"},"reference-count":142,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adoptive immunotherapy with engineered T cells is at the forefront of cancer treatment. T cells can be engineered to express T-cell receptors (TCRs) specific for tumor-associated antigens (TAAs) derived from intracellular or cell surface proteins. T cells engineered with TCRs (TCR-T) allow for targeting diverse types of TAAs, including proteins overexpressed in malignant cells, those with lineage-restricted expression, cancer-testis antigens, and neoantigens created from abnormal, malignancy-restricted proteins. Minor histocompatibility antigens can also serve as TAAs for TCR-T to treat relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Moreover, TCR constructs can be modified to improve safety and enhance function and persistence of TCR-T. Transgenic T-cell receptor therapies targeting 3 different TAAs are in early-phase clinical trials for treatment of hematologic malignancies. Preclinical studies of TCR-T specific for many other TAAs are underway and offer great promise as safe and effective therapies for a wide range of cancers.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000378","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T03:13:32Z","timestamp":1558754012000},"page":"179-190","source":"Crossref","is-referenced-by-count":42,"title":["T-Cell Receptor\u2013Based Immunotherapy for Hematologic Malignancies"],"prefix":"10.1097","volume":"25","author":[{"given":"Melinda A.","family":"Biernacki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Brault","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bleakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","first-page":"326","article-title":"Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line","volume":"3","year":"1943","journal-title":"Cancer Res"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41568-019-0106-z","article-title":"Immune control by amino acid catabolism during tumorigenesis and therapy","volume":"19","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: overcoming the challenges posed by immune evasion","volume":"16","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"bib5-20230924","article-title":"Immune evasion in acute myeloid leukemia: current concepts and future directions","volume":"1","year":"2013","journal-title":"J Immunother Cancer"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3109\/10428194.2014.953150","article-title":"Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics","volume":"56","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","year":"2013","journal-title":"Blood"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.4049\/jimmunol.167.10.6021","article-title":"Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways","volume":"167","year":"2001","journal-title":"J Immunol"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","year":"2018","journal-title":"Leukemia"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies","volume":"24","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","year":"2002","journal-title":"Science"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","year":"1988","journal-title":"N Engl J Med"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-04-3337","article-title":"Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors","volume":"65","year":"2005","journal-title":"Cancer Res"},{"key":"bib17-20230924","first-page":"288ra78","article-title":"Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma","volume":"7","year":"2015","journal-title":"Sci Transl Med"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","article-title":"CD8+ enriched \u201cyoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma","volume":"16","year":"2010","journal-title":"Clin Cancer Res"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.molonc.2015.10.018","article-title":"Tumor-infiltrating lymphocytes for the treatment of metastatic cancer","volume":"9","year":"2015","journal-title":"Mol Oncol"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","year":"2019","journal-title":"Nat Med"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","year":"2018","journal-title":"Science"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","year":"2016","journal-title":"J Clin Invest"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor-modified T cells: CD19 and the road beyond","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","article-title":"Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"200","year":"2018","journal-title":"J Immunol"},{"key":"bib26-20230924","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","year":"2018","journal-title":"Sci Signal"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.0105-2896.2005.00320.x","article-title":"Antigen processing and presentation","volume":"207","year":"2005","journal-title":"Immunol Rev"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nri2368","article-title":"The known unknowns of antigen processing and presentation","volume":"8","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of antigen processing","volume":"31","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.191.6.961","article-title":"Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer","volume":"191","year":"2000","journal-title":"J Exp Med"},{"issue":"suppl 4","key":"bib31-20230924","first-page":"A40","article-title":"HLA class I antigen loss, tumor immune escape and immune selection","volume":"20","year":"2002","journal-title":"Vaccine"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00262-016-1947-x","article-title":"Rejection versus escape: the tumor MHC dilemma","volume":"66","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nbt.3344","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes","volume":"33","year":"2015","journal-title":"Nat Biotechnol"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1399-0039.1998.tb03082.x","article-title":"Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides","volume":"52","year":"1998","journal-title":"Tissue Antigens"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","year":"2017","journal-title":"Nat Commun"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","year":"2017","journal-title":"Cell"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1038\/s41467-018-06300-3","article-title":"Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA","volume":"9","year":"2018","journal-title":"Nat Commun"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.4049\/jimmunol.0803458","article-title":"Autophagy and its role in MHC-mediated antigen presentation","volume":"182","year":"2009","journal-title":"J Immunol"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/jnci\/66.6.1003","article-title":"HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines","volume":"66","year":"1981","journal-title":"J Natl Cancer Inst"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/2326-6066.CIR-15-0243","article-title":"Expression of the MHC class II pathway in triple-negative breast cancer tumor cells is associated with a good prognosis and infiltrating lymphocytes","volume":"4","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-018-2262-5","article-title":"The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth","volume":"68","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.bjc.6600507","article-title":"Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis","volume":"87","year":"2002","journal-title":"Br J Cancer"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti\u2013PD-1\/PD-L1 therapy","volume":"7","year":"2016","journal-title":"Nat Commun"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","year":"2014","journal-title":"Science"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood.V89.4.1405","article-title":"Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia","volume":"89","year":"1997","journal-title":"Blood"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1126\/science.7605428","article-title":"Specific association of human telomerase activity with immortal cells and cancer","volume":"266","year":"1994","journal-title":"Science"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood.V85.9.2315.bloodjournal8592315","article-title":"Telomerase activity in normal leukocytes and in hematologic malignancies","volume":"85","year":"1995","journal-title":"Blood"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1073\/pnas.92.20.9082","article-title":"Telomerase activity in normal and malignant hematopoietic cells","volume":"92","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2016-09-737536","article-title":"TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"77021","DOI":"10.18632\/oncotarget.12778","article-title":"Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"71536","DOI":"10.18632\/oncotarget.12247","article-title":"A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.188.9.1641","article-title":"Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes","volume":"188","year":"1998","journal-title":"J Exp Med"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1084\/jem.20011658","article-title":"Thymic selection generates a large T cell pool recognizing a self-peptide in humans","volume":"195","year":"2002","journal-title":"J Exp Med"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","year":"1997","journal-title":"Immunity"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1046\/j.1365-2141.1998.00982.x","article-title":"PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells","volume":"102","year":"1998","journal-title":"Br J Haematol"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood-2008-06-164889","article-title":"Aurora-A kinase: a novel target of cellular immunotherapy for leukemia","volume":"113","year":"2009","journal-title":"Blood"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2011-06-360354","article-title":"Aurora kinase A\u2013specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity","volume":"119","year":"2012","journal-title":"Blood"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"e1239006","DOI":"10.1080\/2162402X.2016.1239006","article-title":"Novel immunotherapy for adult T-cell leukemia\/lymphoma: targeting Aurora kinase A","volume":"5","year":"2016","journal-title":"Oncoimmunology"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","year":"2019","journal-title":"J Clin Invest"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood-2017-07-791608","article-title":"Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.aaf2288","article-title":"Targeting of cancer neoantigens with donor-derived T cell receptor repertoires","volume":"352","year":"2016","journal-title":"Science"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1182\/blood-2009-12-260539","article-title":"Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","year":"2010","journal-title":"J Exp Med"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/nbt.3662","article-title":"Large-scale detection of antigen-specific T cells using peptide\u2013MHC-I multimers labeled with DNA barcodes","volume":"34","year":"2016","journal-title":"Nat Biotechnol"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/blood-2018-04-843763","article-title":"A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","year":"2016","journal-title":"J Clin Invest"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/mt.2016.51","article-title":"Stable, nonviral expression of mutated tumor neoantigen-specific T-cell receptors using the sleeping beauty transposon\/transposase system","volume":"24","year":"2016","journal-title":"Mol Ther"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ymthe.2018.05.007","article-title":"PiggyBac-engineered T cells expressing CD19-specific CARs that lack IgG1 Fc spacers have potent activity against B-ALL xenografts","volume":"26","year":"2018","journal-title":"Mol Ther"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nm.2128","article-title":"Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy","volume":"16","year":"2010","journal-title":"Nat Med"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.4049\/jimmunol.0902055","article-title":"Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells","volume":"184","year":"2010","journal-title":"J Immunol"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2011-02-337089","article-title":"Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1074-7613(00)80547-6","article-title":"Alanine scanning mutagenesis of an alphabeta T cell receptor: mapping the energy of antigen recognition","volume":"8","year":"1998","journal-title":"Immunity"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.4049\/jimmunol.0804377","article-title":"Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity","volume":"182","year":"2009","journal-title":"J Immunol"},{"key":"bib80-20230924","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1089\/hum.2009.146","article-title":"T cell receptor gene therapy for cancer","volume":"20","year":"2009","journal-title":"Hum Gene Ther"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","year":"2013","journal-title":"Blood"},{"key":"bib82-20230924","first-page":"197ra03","article-title":"Identification of a Titin-derived HLA-A1\u2013presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","year":"2013","journal-title":"Sci Transl Med"},{"key":"bib83-20230924","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ni1401","article-title":"Interface-disrupting amino acids establish specificity between T cell receptors and complexes of major histocompatibility complex and peptide","volume":"7","year":"2006","journal-title":"Nat Immunol"},{"key":"bib84-20230924","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.immuni.2011.10.012","article-title":"A role for differential variable gene pairing in creating T cell receptors specific for unique major histocompatibility ligands","volume":"35","year":"2011","journal-title":"Immunity"},{"key":"bib85-20230924","first-page":"a005140","article-title":"Structural biology of the T-cell receptor: insights into receptor assembly, ligand recognition, and initiation of signaling","volume":"2","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"bib86-20230924","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/nbt.4004","article-title":"Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro","volume":"35","year":"2017","journal-title":"Nat Biotechnol"},{"key":"bib87-20230924","first-page":"922","article-title":"Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function","volume":"8","year":"2002","journal-title":"Clin Cancer Res"},{"key":"bib88-20230924","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","article-title":"The central role of CD4(+) T cells in the antitumor immune response","volume":"188","year":"1998","journal-title":"J Exp Med"},{"key":"bib89-20230924","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-065X.2008.00616.x","article-title":"Multiple roles for CD4+ T cells in anti-tumor immune responses","volume":"222","year":"2008","journal-title":"Immunol Rev"},{"key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"7934","DOI":"10.1073\/pnas.0500357102","article-title":"A critical role of T cell antigen receptor\u2013transduced MHC class I\u2013restricted helper T cells in tumor protection","volume":"102","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib91-20230924","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1158\/0008-5472.CAN-05-4190","article-title":"Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity","volume":"66","year":"2006","journal-title":"Cancer Res"},{"key":"bib92-20230924","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/stem.433","article-title":"An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies","volume":"28","year":"2010","journal-title":"Stem Cells"},{"key":"bib94-20230924","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","year":"2005","journal-title":"Blood"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbmt.2007.04.005","article-title":"Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation","volume":"13","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","article-title":"Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib97-20230924","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/mt.2015.234","article-title":"Serial activation of the inducible caspase 9 safety switch after human stem cell transplantation","volume":"24","year":"2016","journal-title":"Mol Ther"},{"key":"bib98-20230924","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-10-0735","article-title":"Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts","volume":"70","year":"2010","journal-title":"Cancer Res"},{"key":"bib99-20230924","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","year":"2012","journal-title":"Blood"},{"key":"bib100-20230924","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","year":"2015","journal-title":"Clin Cancer Res"},{"key":"bib101-20230924","doi-asserted-by":"crossref","first-page":"1542917","DOI":"10.1080\/2162402X.2018.1542917","article-title":"Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells","volume":"8","year":"2019","journal-title":"Oncoimmunology"},{"key":"bib102-20230924","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-010-0842-0","article-title":"RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells","volume":"59","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"bib103-20230924","doi-asserted-by":"crossref","first-page":"20070","DOI":"10.1038\/srep20070","article-title":"CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients","volume":"6","year":"2016","journal-title":"Sci Rep"},{"key":"bib104-20230924","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2017-04-777052","article-title":"A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib105-20230924","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2017-02-769463","article-title":"c-MPL provides tumor-targeted T-cell receptor\u2013transgenic T cells with costimulation and cytokine signals","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib106-20230924","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","year":"2013","journal-title":"Blood"},{"key":"bib107-20230924","first-page":"1533033819831068","article-title":"The emerging world of TCR-T cell trials against cancer: a systematic review","volume":"18","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"bib108-20230924","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood.V95.1.286","article-title":"HLA class I\u2013restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide","volume":"95","year":"2000","journal-title":"Blood"},{"key":"bib109-20230924","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.V95.7.2198","article-title":"Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1","volume":"95","year":"2000","journal-title":"Blood"},{"key":"bib110-20230924","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood-2007-03-076844","article-title":"Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia","volume":"110","year":"2007","journal-title":"Blood"},{"key":"bib111-20230924","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jim.2005.11.023","article-title":"In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire","volume":"310","year":"2006","journal-title":"J Immunol Methods"},{"key":"bib112-20230924","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/leu.2013.66","article-title":"Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"bib113-20230924","first-page":"174ra27","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","year":"2013","journal-title":"Sci Transl Med"},{"key":"bib114-20230924","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.V128.22.1001.1001","article-title":"EBV-specific donor cells transduced to express a high-affinity WT1 TCR can prevent recurrence in post-HCT patients with high-risk AML","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib115-20230924","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","year":"2019","journal-title":"Nat Med"},{"key":"bib116-20230924","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib117-20230924","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.leukres.2008.08.026","article-title":"Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease","volume":"33","year":"2009","journal-title":"Leuk Res"},{"key":"bib118-20230924","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-11-1066","article-title":"PRAME-specific allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer","volume":"17","year":"2011","journal-title":"Clin Cancer Res"},{"key":"bib120-20230924","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1073\/pnas.0530192100","article-title":"Hematopoiesis-restricted minor histocompatibility antigens HA-1\u2013 or HA-2\u2013specific T cells can induce complete remissions of relapsed leukemia","volume":"100","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib121-20230924","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2000.02328.x","article-title":"Expression and prognostic significance of survivin in de novo acute myeloid leukaemia","volume":"111","year":"2000","journal-title":"Br J Haematol"},{"key":"bib122-20230924","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1182\/blood-2012-02-409888","article-title":"Survivin is highly expressed in CD34(+)38(\u2212) leukemic stem\/progenitor cells and predicts poor clinical outcomes in AML","volume":"120","year":"2012","journal-title":"Blood"},{"key":"bib123-20230924","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/1078-0432.CCR-03-0642","article-title":"High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia","volume":"10","year":"2004","journal-title":"Clin Cancer Res"},{"key":"bib124-20230924","first-page":"1921","article-title":"Prognostic significance of survivin expression in diffuse large B-cell lymphomas","volume":"96","year":"2000","journal-title":"Blood"},{"key":"bib125-20230924","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1200\/JCO.2004.10.172","article-title":"Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"key":"bib126-20230924","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1172\/JCI43437","article-title":"MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors","volume":"120","year":"2010","journal-title":"J Clin Invest"},{"key":"bib127-20230924","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1172\/JCI75876","article-title":"Survivin-specific T cell receptor targets tumor but not T cells","volume":"125","year":"2015","journal-title":"J Clin Invest"},{"key":"bib128-20230924","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ijc.20139","article-title":"Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes","volume":"110","year":"2004","journal-title":"Int J Cancer"},{"key":"bib129-20230924","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2012-11-465971","article-title":"Development of a novel redirected T-cell\u2013based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia","volume":"121","year":"2013","journal-title":"Blood"},{"key":"bib130-20230924","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2009-07-233270","article-title":"Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib131-20230924","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/0008-5472.CAN-15-2318","article-title":"Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies","volume":"76","year":"2016","journal-title":"Cancer Res"},{"key":"bib132-20230924","doi-asserted-by":"crossref","first-page":"86987","DOI":"10.18632\/oncotarget.18115","article-title":"Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib133-20230924","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2141.2003.04311.x","article-title":"Aurora2\/BTAK\/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"bib134-20230924","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","year":"2013","journal-title":"Nature"},{"key":"bib135-20230924","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/leu.2014.233","article-title":"Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy","volume":"29","year":"2015","journal-title":"Leukemia"},{"key":"bib136-20230924","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood-2018-07-866830","article-title":"The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib137-20230924","doi-asserted-by":"crossref","first-page":"e1316438","DOI":"10.1080\/2162402X.2017.1316438","article-title":"HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy","volume":"7","year":"2018","journal-title":"Oncoimmunology"},{"key":"bib138-20230924","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","article-title":"Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction","volume":"46","year":"2017","journal-title":"Immunity"},{"key":"bib139-20230924","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1021\/pr700761w","article-title":"Identification of breast cancer peptide epitopes presented by HLA-A*0201","volume":"7","year":"2008","journal-title":"J Proteome Res"},{"key":"bib140-20230924","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.4049\/jimmunol.1501721","article-title":"The length distribution of class I\u2013restricted T cell epitopes is determined by both peptide supply and MHC allele-specific binding preference","volume":"196","year":"2016","journal-title":"J Immunol"},{"key":"bib141-20230924","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature22383","article-title":"Quantifiable predictive features define epitope-specific T cell receptor repertoires","volume":"547","year":"2017","journal-title":"Nature"},{"key":"bib142-20230924","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"bib143-20230924","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib144-20230924","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jcyt.2016.05.001","article-title":"A novel TCR-like CAR with specificity for PR1\/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells","volume":"18","year":"2016","journal-title":"Cytotherapy"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201905000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T16:54:21Z","timestamp":1721321661000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201905000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":142,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000378","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}